Skip to Content

Immune Therapeutics Inc IMUN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Immune Therapeutics Inc is a specialty pharmaceutical company operating in the USA. It engages in the commercialization of patented therapies focused on the activation and re-balancing of the body's immune system. The company is involved in acquiring the patent for the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (LDN) and Methionine [Met5]-enkephalin (MENK). It focuses on to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. The company's technology platform is built on various immunotherapies, such as Low Dose Naltrexone and Methionine-Enkephalin. It markets Low Dose Naltrexone under the IRT-103 brand.

Contact
2431 Aloma Avenue, Suite 124
Winter Park, FL, 32792
T +1 888 613-8802
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Slow Growth
Employees 4